| Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia H Kantarjian, A Stein, N Gökbuget, AK Fielding, AC Schuh, JM Ribera, ... New England Journal of Medicine 376 (9), 836-847, 2017 | 1780 | 2017 |
| Retinoic acid and arsenic trioxide for acute promyelocytic leukemia F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ... New England Journal of Medicine 369 (2), 111-121, 2013 | 1651* | 2013 |
| Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease JJM Van Dongen, EA Macintyre, JA Gabert, E Delabesse, V Rossi, ... Leukemia 13 (12), 1901-1928, 1999 | 1534 | 1999 |
| Idecabtagene vicleucel in relapsed and refractory multiple myeloma NC Munshi, LD Anderson Jr, N Shah, D Madduri, J Berdeja, S Lonial, ... New England Journal of Medicine 384 (8), 705-716, 2021 | 1429 | 2021 |
| Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study MS Topp, N Gökbuget, AS Stein, G Zugmaier, S O'Brien, RC Bargou, ... The Lancet Oncology 16 (1), 57-66, 2015 | 1284 | 2015 |
| Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis A Tefferi, P Guglielmelli, DR Larson, C Finke, EA Wassie, L Pieri, ... Blood, The Journal of the American Society of Hematology 124 (16), 2507-2513, 2014 | 820 | 2014 |
| Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study A Tefferi, E Rumi, G Finazzi, H Gisslinger, AM Vannucchi, F Rodeghiero, ... Leukemia 27 (9), 1874-1881, 2013 | 811 | 2013 |
| Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis J Golay, L Zaffaroni, T Vaccari, M Lazzari, GM Borleri, S Bernasconi, ... Blood, The Journal of the American Society of Hematology 95 (12), 3900-3908, 2000 | 792 | 2000 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 680 | 2019 |
| Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis) T Barbui, G Finazzi, A Carobbio, J Thiele, F Passamonti, E Rumi, ... Blood, The Journal of the American Society of Hematology 120 (26), 5128-5133, 2012 | 657 | 2012 |
| Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia AM Vannucchi, E Antonioli, P Guglielmelli, A Rambaldi, G Barosi, ... Blood, The Journal of the American Society of Hematology 110 (3), 840-846, 2007 | 633 | 2007 |
| Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia Italian Cooperative Study Group on Chronic Myeloid Leukemia New England Journal of Medicine 330 (12), 820-825, 1994 | 607 | 1994 |
| CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 J Golay, M Lazzari, V Facchinetti, S Bernasconi, G Borleri, T Barbui, ... Blood, The Journal of the American Society of Hematology 98 (12), 3383-3389, 2001 | 555 | 2001 |
| Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) R Bassan, O Spinelli, E Oldani, T Intermesoli, M Tosi, B Peruta, G Rossi, ... Blood, The Journal of the American Society of Hematology 113 (18), 4153-4162, 2009 | 525 | 2009 |
| Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among … RM Emanuel, AC Dueck, HL Geyer, JJ Kiladjian, S Slot, S Zweegman, ... Journal of clinical oncology 30 (33), 4098-4103, 2012 | 517 | 2012 |
| ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned S Viviani, PL Zinzani, A Rambaldi, E Brusamolino, A Levis, V Bonfante, ... New England Journal of Medicine 365 (3), 203-212, 2011 | 500 | 2011 |
| MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis P Guglielmelli, TL Lasho, G Rotunno, M Mudireddy, C Mannarelli, ... Journal of Clinical Oncology 36 (4), 310-318, 2018 | 494 | 2018 |
| Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden AM Vannucchi, E Antonioli, P Guglielmelli, G Longo, A Pancrazzi, ... Leukemia 21 (9), 1952-1959, 2007 | 473 | 2007 |
| Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice M Morigi, M Introna, B Imberti, D Corna, M Abbate, C Rota, D Rottoli, ... Stem cells 26 (8), 2075-2082, 2008 | 471 | 2008 |
| PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia Z Gu, ML Churchman, KG Roberts, I Moore, X Zhou, J Nakitandwe, ... Nature genetics 51 (2), 296-307, 2019 | 458 | 2019 |
martino intronaQualified Person, Centro di Terapia Cellulare "G. Lanzani" ASST Papa Giovanni XXIII Bergamo ItalyVerifierad e-postadress på asst-pg23.it
